

- Screening tests, 2, 26. *See also specific diseases and tests*
 adverse outcomes of, 28
 age-specific recommendations, 30–31t
 evidence-based recommendations for, 28–30, 29t
 health benefits of, 27–28, 28t
 principles of, 27t, 29
 Screening trials, 480
 Screwworm fly, 2747
 Scrub typhus
 clinical features of, 128t, 152e-3t, 1155t, 1159, 1561
 diagnosis of, 152e-3t, 1159
 epidemiology of, 128t, 1155t, 1159
 etiology of, 782, 1155t, 1159
 incubation period for, 152e-3t
 prevention of, 152e-3t
 rash in, 128t, 135, 782, 1159
 in returning war veterans, 152e-3t
 treatment of, 152e-3t, 1159
 Scurvy
 clinical features of, 96e-1t, 96e-5, 461, 732
 etiology of, 96e-5
 oral manifestations of, 237
 skin manifestations of, 367, 436e-1f, 463t
 treatment of, 96e-5
 SDF (stromal cell-derived factor), 372e-12t, 1235
 SDHB gene mutations, 2332, 2334f, 2335, 2344
 SDHC gene mutations, 2334f
 SDHD gene mutations, 2332, 2334–2335, 2334f
 SDH (succinate dehydrogenase) enzyme, 2329, 2332
 Sea anemone envenomation, 2738
 Seabather's eruption, 2741, 2741f
 Sea cucumber envenomation, 2740
 Seadornaviruses, 1305, 1310t
 Seal bite-wound, 167e-1, 167e-3
 Sea levels, rise in, 151e-3
 Seal finger, 167e-1, 167e-3
 Sealpox, 220e-1t
 Sea snake envenomation, 2734
 Seasonal affective disorder, 2715
 Sea sponge, 2739
 Sea urchins, 2739–2740, 2741f
 Sebaceous adenoma, 364t, 365
 Sebaceous carcinoma, 365
 Sebaceous hyperplasia, 365
 Sebastian's syndrome, 729
 Sebopsoriasis, 347
 Seborrheic dermatitis, 347
 clinical features of
 distribution and morphology of skin lesions, 341t, 342f, 347, 354t
 erythroderma, 354t
 facial, 76e-2f, 347f
 in HIV infection, 1262
Malassezia infection in, 1357
 treatment of, 347, 354t
 Seborrheic keratosis, 76e-3f, 341t, 342f, 359, 360t
 Secobarbital, 473e-10t
 Secondary taste cortex, 214
 Second disease. *See* Scarlet fever (second disease)
 Second-hand smoke. *See* Smoking, passive exposure to
 Second impact syndrome, 457e-4, 471e-5–6
 Secretin test, 2087t, 2100
 Secretion defects, 730
 Secretory diarrhea, 268–269, 268t, 303, 1933. *See also* Diarrhea
 Secretory leukocyte protease inhibitor (SLPI), 1223
 Secretory protein, 372e-22
 Secukinumab, 2173, 2177
 Sedation
 of critically ill patient, 1782
 of mechanically ventilated patient, 1732–1733, 1741, 1743
 for myocardial infarction, 1606
 Sedative-hypnotics, 473e-3, 473e-10t. *See also specific drugs*
 Segawa variant (dopa-responsive) dystonia, 434e-2t, 2620
 Seizure(s), 2542. *See also* Epilepsy
 absence, 2543
 after head injury, 457e-2–3
 in alcohol withdrawal, 2728
 approach to the patient, 2548, 2549f
 atonic, 2543–2544
 in brain abscess, 901
 in brain tumor, 598
 in cancer patient, 1793
 chemotherapy-induced, 607t
 classification of, 2542–2543, 2542t
 coma in, 1773
 continuous. *See* Status epilepticus
 definition of, 2542
 delirium and, 169, 2607
 differential diagnosis of, 2550–2551, 2551t
 eclamptic, 46
 EEG in, 442e-1–2, 442e-2f, 2550
 etiology of, 2544–2547, 2546t, 2547t
 evolution from focal seizures, 2543
 febrile, 126, 2545–2546
 focal, 2542–2543, 2586
 focal sensory, 162
 generalized, 2543
 in head injury, 2547
 in heatstroke, 479e-3
 history and examination in, 2548–2550
 in HIV infection, 1265, 1265t
 in hyperperfusion syndrome, 463e-1
 imaging in, 2550
 laboratory studies in, 2550
 lactic acidosis in, 318
 magnetoencephalography in, 442e-3, 2550
 in malaria, 1373
 mechanisms of, 2547–2548
 in meningitis, 887
 myoclonic, 2544
 in neurocysticercosis, 1430–1431, 1432
 in overdose/poisoning, 473e-3, 473e-5
 in pregnancy, 46, 49
 psychogenic, 2551
 pyridoxine-dependent, 434e-3t
 vs. syncope, 147, 2550–2551, 2551t
 temporal lobe, 183
 tonic-clonic, 2543
 treatment of, 2551. *See also* Epilepsy, treatment of
 unclassifiable, 2544
 Selectins, 139e-1, 416, 417f
 Selection bias, 480
 Selective AR modulators, 2371
 Selective digestive decontamination, in burn patients, 166e-3
 Selective estrogen response modulators (SERMs)
 action of, 102e-4f, 102e-7, 2499
 in osteoporosis management/prevention, 2498–2499
 Selective IgA deficiency, 2112
 Selective serotonin reuptake inhibitors (SSRIs)
 adverse effects of, 2710t, 2716
 serotonin syndrome. *See* Serotonin syndrome
 sexual dysfunction, 327, 2716
 SIADH, 300
 for dementia, 175
 for depression, 2710t, 2716, 2716f
 for depression in AD, 2602
 for depression in terminally ill patient, 64
 drug interactions of, 40, 2711t, 2717
 genetic variations in response to, 40
 for inappropriate sinus tachycardia, 1477
 for irritable bowel syndrome, 1969, 1970t
 overdose/poisoning with, 473e-13t
 for pain, 94
 pharmacology of, 2716–2717
 for premature ejaculation, 325
 for PTSD, 471e-4–5, 2712
 for vertigo, 151, 151t
 Selegiline
 adverse effects of, 2710t
 for depression, 2710t, 2717
 overdose/poisoning with, 473e-8t
 for PD, 2615, 2616t
 Selenium, 96e-10
 deficiency of, 96e-9t, 96e-10, 533, 1563
 dietary sources of, 96e-10
 parental supplementation of, 98e-6t
 for prostate cancer prevention, 478
 recommended intake of, 95e-3t
 reference range for, 2766t
 tolerable upper intake level of, 96e-9t
 toxicity of, 96e-9t, 96e-10
 Selenium sulfide
 for tinea capitis, 355t
 for tinea versicolor, 350, 350t, 358t
 Selenocysteine, 96e-10
 Selenosis, 96e-10
 Self-renewal, of stem cells, 453
 Seligman's disease (alpha heavy chain disease), 537, 718–719
 Sella chordomas, 2264
 Sellar fractures, 457e-2
 Sellar mass lesions, 2261. *See also specific lesions*
 clinical features of, 2261–2262, 2261t
 histologic investigation of, 2262
 hypogonadotropic hypogonadism and, 2365
 laboratory investigation of, 2262
 MRI in, 2262, 2262f
 ophthalmologic evaluation in, 2262
 Semantic dementia, 182
 Semantic paraphasia, 177
 Semen analysis, 2361, 2388
 Seminiferous tubules, 2358f, 2359–2360
 Seminoma. *See* Testicular cancer
 Semliki Forest virus, 1306t
 Senescence. *See also* Aging
 carcinogenesis and, 102e-1t, 102e-3
 definition of, 102e-8
 negligible, 94e-2, 94e-2f
 Senile purpura, 732
 Senior-Löken syndrome, 1850t, 1855
 Senna, 61, 62t, 273
 Sennetsu fever, 1159
 Sensation
 abnormalities of, 158
 in brainstem lesions, 161
 in cortical lesions, 161–162
 falls and, 165
 in focal seizures, 162
 localization of, 160–161
 in nerve and root lesions, 161
 in spinal cord lesions, 161
 in thalamic lesions, 161
 anatomy of, 158, 159f, 160f, 161f
 examination of, 158
 cortical, 159–160
 primary, 159, 160t
 quantitative sensory, 159
 positive and negative phenomena, 158
 terminology in, 158
 Sensenbrenner's syndrome (cranioectodermal dysplasia), 1850t
 Sensitivity
 analytical, 480e-2
 of tests, 21, 22, 479, 479t
 Sensitization, 87, 2114
 Sensory afferents, 47e-1
 Sensory ataxia, 158, 163, 164t
 Sensory ataxic neuropathy and ophthalmoparesis (SANDO), 451e-2t
 Sensory balance training, 163
 Sensory dissociation, 161
 Sensory examination, 2539
 Sensory neuropathy. *See* Peripheral neuropathy
 Sentinel acute pancreatitis event (SAPE) hypothesis, 2098
 Sentinel bleeds, subarachnoid, 1785
 Sentinel lymph node biopsy, 103e-3, 496–497, 528
 Seoul virus, 1307t
 Sepsis/septic shock, 1751
 anaerobic bacteremia and, 1100
 clinical features of, 780t, 781–783, 1754–1755
 clostridial, 991t, 994